Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
10.44
+0.54 (5.45%)
At close: May 12, 2025, 4:00 PM
10.44
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
Cartesian Therapeutics Employees
Cartesian Therapeutics had 66 employees as of December 31, 2024. The number of employees increased by 28 or 73.68% compared to the previous year.
Employees
66
Change (1Y)
28
Growth (1Y)
73.68%
Revenue / Employee
$517,773
Profits / Employee
-$580,455
Market Cap
270.18M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66 | 28 | 73.68% |
| Dec 31, 2023 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNAC News
- 4 days ago - Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 10 days ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 4 weeks ago - Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - GlobeNewsWire
- 5 weeks ago - Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - GlobeNewsWire
- 5 months ago - Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial - GlobeNewsWire